BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Dear Doctor Letter (Rote-Hand-Brief) on hydrochlorothiazide: risk of non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma)

2018.10.17

Active substance: hydrochlorothiazide

Marketing authorisation holders of the products containing hydrochlorothiazide would like to inform about pharmacoepidemiological studies which have shown a risk of non-melanoma skin cancer (NMSC) (basal cell carcinoma, squamous cell carcinoma) with exposure to increasing cumulative doses of hydrochlorothiazide (HCTZ).

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 3MB, File is accessible